Volz 1997.

Methods	Randomised, placebo‐controlled double‐blind, multicenter; 2 parallel groups
Participants	Outpatients with nonpsychotic anxiety (DSM‐III‐R); HAMA total score 19 or above (intention‐to‐treat; n=100); General practice, Germany
Interventions	100 mg 3 times (210 mg kavalactones) daily for 24 weeks
Outcomes	HAM‐A total score. Mean difference, 95% confidence interval 4.8; ‐0.6 to 10.2
Notes	Adverse events (kava group): not detailed; stomach upset were rated by the investigators as possibly related to the intake of kava Jadad score: 3
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear